Longevity Venture Partners

The firm concentrates exclusively on extending healthy human lifespan through early-stage venture investments. Its thesis targets the biology of aging across therapeutic development, diagnostic platforms, and AI-enabled drug discovery. This pure-play approach means it does not diversify into general biotech or healthtech sectors outside the longevity umbrella.

Specific sourcing channels are not publicly detailed. Given its Baltimore location and concentrated thesis, deal flow likely originates from academic research institutions, biotechnology incubators, and aging-focused scientific networks. The firm's narrow mandate typically attracts founders working on geroscience rather than those seeking broad life-science capital.

The firm's participation posture is not publicly confirmed. Early-stage longevity vehicles of similar size often prefer co-investment or syndicate participation alongside larger biotech funds. Without direct disclosure, the firm's lead-investor appetite remains unverified.

The firm focuses on seed and Series A rounds, consistent with early-stage venture mandates in biotechnology. Companies at these stages are typically preclinical or early clinical in therapeutic development, or pre-revenue in diagnostic and digital-health applications.

By structural design, the firm avoids any sector outside the longevity economy. This excludes general biotechnology, medical devices not directly tied to aging mechanisms, late-stage pharmaceuticals, and health IT platforms without a geroscience or lifespan-extension component.